- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02130778
Natriuretic Effect of GLP-1in Healthy Non Obese Subjects
Natriuretic Effect of GLP-1 in Healthy Non Obese Subjects Followed by Oral Sodium Load: A Randomized, Placebo-controlled, Cross-over Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a cross-over study. Totally 15 participants will be randomized (or other number later determined by power test). The duration of the study is 9 days that will include 3 visits and screening visit before starting the study.
Screening (day -1) Inclusion criteria are fulfilled before approaching Visit 1 on screening. Participants are instructed do come next day fasting and to collect 24h of urine sample.
Visit 1 (day 1) Participant voluntarily agrees to participate by giving informed written consent. Baseline study assessment is going to be performed fasting: blood count and differential, blood chemistry (liver enzymes, sodium, potassium, calcium, phosphorus, magnesium, chloride, serum amorality, urea and creatinine, lipid panel including cholesterol, triglycerides, HDL and LDL cholesterol, coagulation, uric acid, glucose and insulin, renin activity, aldosterone, GLP1 level, T4 TSH-thyroid stimulating hormone, ADH, BNP) In the 24 h urine collection sodium, chloride and calcium excretion, osmolality, creatinine are going to be measured, glomerular filtration is going to be assessed by creatinine clearance, urin analysis with microscopy is going to be preformed, EKG, kidney ultrasound together with 24-h blood pressure monitor. HOMA2 (The Homeostasis Model Assessment ) index is calculated and a total body water percentage determinated via Bioelectrical Impedance Analysis. All samples of renin activity and aldosterone in a study are going to be taken while being in horizontal position at least for 3 hours. Participants are going to be randomized regarding the glucose tolerance test. First group it the one with fasting glucose 4,5 -5,7 mmol/L and at 2 hour OGTT (the amount of sodium in OGTT fluid used is 0,4 mg of sodium and 0,3 mg of chloride in 0,2 L of water) glucose level below 7.8 mmol/l. The other group is the one with fasting glucose from 5,7 to 7 mmol/l and/or at 2 hour OGTT glucose level form 7.8 mmol/l to 11,1 mmol/L (venous sample). Patients are instructed to come on the next day fasting again.
Visit 2 (day 2) is a next study assessment: 24-h blood pressure monitor is removed, after the overnight fast oral saline load is going to be given in a form of a standardized meal (soup) in a amount of 12 g of NaCl (average daily intake of salt in Croatia). The soup is going to be consumed in 30 minutes. Volunteers are going to be instructed to drink afterwards 1/2 L of water during next 1 h. Placebo in a form iv infusion of hypertonic saline is going to be given at a rate of 0.06 ml/kg/in and infused during 3 hours from beginning of oral sodium load. During 6 hours (from oral sodium load) urine is gong to be collected. Finally, blood samples are going to be drawn for glucose, insulin, sodium, potassium, serum osmolality, serum creatinine, renin activity, and aldosterone, BNP, ADH and GLP1 level after 3 and 6 hours. Sodium, chloride and calcium excretion, osmolality and creatinine are going to be measured in the urine after 3 hours. Patients are instructed to come again after 7 days fasting.
Visit 3 (day 9) after the overnight fast again oral sodium load is going to be given in a form of a standardized meal (soup) in a same amount as previous day and again consumed in 30 minutes, they are going to drink afterwards 1/2 L of water during next 1 h like pervious day. Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline is going to be infused during 3 hours from beginning of oral sodium load. During 6 hours (from oral sodium load) urine is gong to be collected, blood samples are going to be drawn after 3 and 6 hours for the same analysis as in Visit 2, just like urine collection after 6 hours.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Zagreb, Croatia, 10000
- University Hospital Centre Zagreb
-
Zagreb, Croatia, 10 000
- University Hospital Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria:
- Participant is ≥18 and ≤70 years of age on day of signing informed consent
Participant is a male, or a female who is unlikely to conceive, as indicated by at least one "yes" answer to the following questions:
- Patient is a surgically sterilized female
- Patient is a postmenopausal female ≥45 years of age with >2 years since last menses
- Patient is a non-sterilized, premenopausal female and agrees to abstain from heterosexual activity or to use an adequate method of contraception ( Note: Acceptable methods of birth control are: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy)
- BMI ≥185 and ≤25
Healthy as determined by:
- Complete medical history, physical exam and
- Standard 12-lead EKG
- Complete blood count, blood chemistry , urinalysis with microscopy
- Kidney USG
- Participant understands the study procedures, and risks involved with the study and voluntarily agree to participate by giving informed written consent.
Exclusion Criteria:• History of hypertension, diabetes (ADA guidelines), kidney disease
o Participant has impaired renal function defined as glomerular filtration lower than 90 calculated by Cockcroft-Gault formula and 24 creatinine, also by urinary protein excretion > 200 mg/day or continuing active urinary sediment
- History of myocardial infarction, cerebrovascular accident or transient ischemic attack
- History of malignancy within last 5 years
- Current febrile state
- Participant is pregnant or nursing woman
- Failure to give informed consent or comply with the protocol
- Participant has received treatment with an investigational drug within the prior 3 months or is otherwise participating in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Saline infusion
infusion of saline
|
infusion of saline
|
Active Comparator: Saline infusion with GLP1
infusion of saline with GLP1
|
infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evidence of the positive effect on natriuresis (level of sodium in urin sample) following the of GLP1 infusion
Time Frame: Within the 10 minutes after the infusion synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
|
Within the 10 minutes after the infusion synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004 Jun;89(6):3055-61. doi: 10.1210/jc.2003-031403.
- Baretic M, Kusec V, Pavlic-Renar I. Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study. Diabetes Ther. 2018 Dec;9(6):2315-2324. doi: 10.1007/s13300-018-0517-y. Epub 2018 Oct 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- UHCZagreb
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sodium Excretion by Urination
-
Universidad Complutense de MadridEnrolling by invitationBody Weight | Urinary Sodium Excretion | Salt IntakesSpain
-
Beijing Children's HospitalCapital Medical UniversityCompletedUrinary Sodium Excretion | Salt IntakesChina
-
Abbott Point of CareCompletedAnalytical Performance of Sodium, Glucose and Hematocrit Assays by the i-STAT 500 (Alinity) AnalyzerUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedGastrointestinal Cancer | CALCIUM LEVOFOLINATO (Ca-lev) | SODIUM LEVOFOLINATO (Na-lev)
-
Tanta UniversityNot yet recruitingSodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
-
Chang Gung Memorial HospitalRecruitingHead and Neck Squamous Cell Carcinoma | Selenium | Sodium SeleniteTaiwan
-
Sun Yat-sen UniversityNot yet recruiting
-
Charite University, Berlin, GermanyGerman Heart InstituteCompletedHypertension | Renal Cell Cancer Metastatic | Sodium ImbalanceGermany
-
BayerActive, not recruitingLiver Metastases | Metastatic Pancreatic Cancer | Gadoxetate Sodium-enhanced Magnetic Resonance ImagingJapan
-
First Affiliated Hospital of Jinan UniversityRuijin HospitalRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | P53 Mutation | Myeloid Malignancy | Temperature-Sensitive p53 Mutation | Sodium StibogluconateChina
Clinical Trials on 500 ml 0.9% saline
-
Tri-Service General HospitalCompleted
-
Centre Hospitalier Universitaire, AmiensCompletedHepatic Flow ChangesFrance
-
Jeffrey Alan Klein, MDNot yet recruitingAnesthesia, Local | Injection Site Irritation | Injection Site Discomfort | Injection Site Bruising | Benzoic Acid Adverse ReactionUnited States
-
Taipei Medical UniversityCompleted
-
Ottawa Hospital Research InstituteThe Physicians' Services Incorporated Foundation; The Kidney Foundation of... and other collaboratorsRecruitingCritical Illness | Acute Kidney Injury | Hypotension | Renal Replacement TherapyCanada
-
Ampio Pharmaceuticals. Inc.CompletedKnee Osteoarthritis | Osteoarthritis, Knee | Knee Arthritis | Knee Pain ChronicUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Rigshospitalet, DenmarkCompletedAppetitive Behavior | Physical Stress | Interleukin-6 InhibitionDenmark
-
Arcispedale Santa Maria Nuova-IRCCSAzienda Sanitaria OspedalieraCompletedContrast Induced NephropathyItaly
-
Seoul National University HospitalGreen Cross Corporation; LSK Global Pharma Services Co. Ltd.Completed